AZ picks up $350m after selling hypertension drugsAstraZeneca has picked up a $350m windfall after selling off five hypertension medicines to generics specialist Atnahs Pharma. Share XAZ picks up $350m after selling hypertension drugshttps://pharmaphorum.com/news/az-picks-up-350m-after-selling-hypertension-drugs/
FDA approves Caption Health’s AI-driven cardiac ultrasound softwareThe FDA has approved software from medical artificial intelligence (AI) firm Caption Health, that allows medical professionals without Share XFDA approves Caption Health’s AI-driven cardiac ultrasound softwarehttps://pharmaphorum.com/news/fda-approves-caption-healths-ai-driven-cardiac-imaging-software/
NICE backs Medtronic’s AF monitor in post-stroke patientsEngland’s NHS could prevent hundreds of strokes of unknown cause with a new implantable monitor that transmits data Share XNICE backs Medtronic’s AF monitor in post-stroke patientshttps://pharmaphorum.com/news/nice-backs-medtronics-af-monitor-in-post-stroke-patients/
AZ axes phase 3 heart disease trial of fish oil drug EpanovaAstraZeneca has axed a large late-stage trial for its heart disease drug Epanova in patients with mixed dyslipidemia Share XAZ axes phase 3 heart disease trial of fish oil drug Epanovahttps://pharmaphorum.com/news/az-axes-phase-3-trial-in-heart-disease/
AZ and Novoheart collaborate on ‘heart in a jar’, to develop new HF drugsStem cell biotech Novoheart is to collaborate with AstraZeneca to develop a “heart in a jar” that will Share XAZ and Novoheart collaborate on ‘heart in a jar’, to develop new HF drugshttps://pharmaphorum.com/news/az-and-novoheart-collaborate-on-heart-in-a-jar-to-d/
Novartis eyes $5bn The Medicines Company acquisition – reportsNovartis is leading a group of companies that are considering buying US pharma The Medicines Company searching for Share XNovartis eyes $5bn The Medicines Company acquisition – reportshttps://pharmaphorum.com/news/novartis-eyes-5bn-the-medicines-company-acquisition-reports/
Amgen pulls higher-priced Repatha to try to lift salesMore than four years after Amgen’s cholesterol-lowering antibody Repatha was approved in the US, the company still can’t Share XAmgen pulls higher-priced Repatha to try to lift saleshttps://pharmaphorum.com/news/amgen-pulls-higher-priced-repatha-to-try-to-lift-sales/
FDA approves AZ’s Farxiga in new heart failure prevention useThe FDA has approved AstraZeneca’s diabetes drug Farxiga to reduce the chances of hospitalisations for heart failure in Share XFDA approves AZ’s Farxiga in new heart failure prevention usehttps://pharmaphorum.com/news/fda-approves-azs-farxiga-in-new-heart-failure-prevention-use/
AI-driven atrial fibrillation project begins after seed funding roundClinical development of an AI-driven system that identifies the sources or drivers of atrial fibrillation (AF), and could Share XAI-driven atrial fibrillation project begins after seed funding roundhttps://pharmaphorum.com/news/ai-driven-atrial-fibrillation-project-begins-after-seed-funding-round/
